Indaptus Therapeutics (INDP) EPS (Basic) Growth (1y) (2021 - 2026)
Indaptus Therapeutics (INDP) EPS (Basic) Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | -16.29% |
| 10 | Indaptus Therapeutics | 145.16 Mn | 133.61 Mn | - | 99.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 99.83% |
| Mar 31, 2026 | 97.78% |
| Dec 31, 2025 | 32.61% |
| Sep 30, 2025 | 72.19% |
| Jun 30, 2025 | 36.86% |
| Mar 31, 2025 | 36.86% |
| Dec 31, 2024 | 10.36% |
| Sep 30, 2024 | 40.08% |
| Jun 30, 2024 | -20.16% |
| Mar 31, 2024 | -1.63% |
| Dec 31, 2023 | -5.27% |
| Sep 30, 2023 | -34.55% |
| Jun 30, 2023 | 11.53% |
| Mar 31, 2023 | -19.64% |
| Dec 31, 2022 | 40.00% |
| Sep 30, 2022 | 59.60% |
| Jun 30, 2022 | 99.99% |
| Mar 31, 2022 | 99.99% |
| Dec 31, 2021 | -93.45% |
| Sep 30, 2021 | -32.14% |